Abstract
Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Volume: 12 Issue: 3
Author(s): Huang Jiaguo, Liu Zhiguo and Zeng Wenbin
Affiliation:
Keywords: Histone deacetylase, Histone deacetylase inhibitors, Cancer therapy, Molecular imaging, PET, Optical imaging, TOMO- GRAPHY, Myeloma, Colon Carcinoma, Brain Cancer
Abstract: Molecules that inhibit histone deacetylases (HDACs) activity have shown a great promise as anticancer agents since they interfere with cell proliferation and angiogenesis, induce cell differentiation and promote apoptosis. A number of HDACIs (for example: SAHA) have been approved by FDA for the treatment of cancer in different stages of clinical trials. HDAC inhibition proves to be a worthy strategy for cancer therapy. Thus, the distribution and metabolism of HDACIs in vivo are of significant clinical value for diagnosis and assessment of therapeutic efficacy. Molecular imaging is one of the primary tools used to noninvasively evaluate biological processes at the cellular and molecular level in living subjects. Various imaging modalities, including optical bioluminescence/ fluorescence, PET, SPECT, MRI, CT and US are all successfully used to assess the anatomic or functional dissemination of tissues and specific molecular targets, such as imaging molecular interactions, tumor vitality, apoptosis, angiogenesis and response to cancer treatment in the body. The utility of molecular imaging for monitoring HDACIs provides a perfect strategy for deeper understanding about cancer. In this article, the recent progresses of molecular imaging for assessing HDACIs are reviewed. In addition, how imaging can be used, at least experimentally, to assess specific molecular targets is also discussed.
Export Options
About this article
Cite this article as:
Jiaguo Huang, Zhiguo Liu and Wenbin Zeng, Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228779
DOI https://dx.doi.org/10.2174/187152012800228779 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Expression of P-gp in Glioblastoma: What we can Learn from Brain Development
Current Pharmaceutical Design Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment
Current Drug Targets Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets The Role of microRNAs in Gliomas – Therapeutic Implications
Current Molecular Pharmacology Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets